Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-2103 vs paclitaxel in chemotherapy-naïve women with advanced NSCLC (PS 2)
2005-005233-35Phase 3Terminated
- Sponsor
- CTI BioPharma Corp.
- Start
- Dec 2005
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised trial of paclitaxel poliglumex in non-small cell lung cancer (NSCLC) (2 arms), sponsored by CTI BioPharma Corp. Primary endpoint: Overall survival. Started Dec 2005; status: terminated.
02
Drugs
paclitaxel poliglumex
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2005-005233-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005233-35.